
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Diabetol</journal-id><journal-title-group><journal-title>Cardiovascular Diabetology</journal-title></journal-title-group><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31604444</article-id><article-id pub-id-type="pmc">6787962</article-id><article-id pub-id-type="publisher-id">939</article-id><article-id pub-id-type="doi">10.1186/s12933-019-0939-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Hypomagnesemia is associated with new-onset diabetes mellitus following heart transplantation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Peled</surname><given-names>Yael</given-names></name><address><phone>972-3-5302710</phone><email>yaelpotash@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ram</surname><given-names>Eilon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lavee</surname><given-names>Jacob</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tenenbaum</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fisman</surname><given-names>Enrique Z.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Freimark</surname><given-names>Dov</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Klempfner</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sternik</surname><given-names>Leonid</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shechter</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2107 2845</institution-id><institution-id institution-id-type="GRID">grid.413795.d</institution-id><institution>Leviev Cardiothoracic and Vascular Center, </institution><institution>Sheba Medical Center, </institution></institution-wrap>Tel Hashomer, Israel </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0546</institution-id><institution-id institution-id-type="GRID">grid.12136.37</institution-id><institution>Sackler Faculty of Medicine, </institution><institution>Tel Aviv University, </institution></institution-wrap>Tel Aviv, Israel </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>18</volume><elocation-id>132</elocation-id><history><date date-type="received"><day>19</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Diabetes mellitus (DM) is a major cause of morbidity and mortality following heart transplantation (HT), with 21% and 35% of survivors being affected within 1 and 5&#x000a0;years following HT, respectively. Magnesium deficiency is common among HT patients treated with calcineurin inhibitors and is a known risk factor for DM in non-HT patients. We therefore investigated the association between serum Mg (s-Mg) levels and new-onset diabetes after transplantation (NODAT).</p></sec><sec><title>Methods</title><p id="Par2">Between 2002 and 2017, 102 non-DM HT patients were assessed. In accordance with the mean value of all s-Mg levels recorded during the first year post-HT, patients were divided into high s-Mg (&#x02265;&#x02009;1.8&#x000a0;mg/dL) and low s-Mg (&#x0003c;&#x02009;1.8&#x000a0;mg/dL) groups. The endpoint was NODAT, defined according to the diagnostic criteria of the American Diabetes Association.</p></sec><sec><title>Results</title><p id="Par3">Baseline clinical and demographic characteristics for the high (n&#x02009;=&#x02009;45) and low s-Mg (n&#x02009;=&#x02009;57) groups were similar. Kaplan&#x02013;Meier survival analysis showed that 15-year freedom from NODAT was significantly higher among patients with high vs low s-Mg (85% vs 46% log-rank test, p&#x02009;&#x0003c;&#x02009;0.001). Consistently, multivariate analysis adjusted for age, gender, immunosuppression therapies, BMI and mean creatinine values in the first year post-HT, showed that low s-Mg was independently associated with a significant &#x0003e;&#x02009;8-fold increased risk for NODAT (95% CI 2.15&#x02013;32.63, p&#x02009;=&#x02009;0.003). Stroke rate was significantly higher in patients with low s-Mg levels vs high s-Mg (14% vs 0, p&#x02009;=&#x02009;0.025), as well as long term mortality (HR 2.6, 95% CI 1.02&#x02013;6.77, p&#x02009;=&#x02009;0.05).</p></sec><sec><title>Conclusions</title><p id="Par4">Low s-Mg level post-HT is an independent risk factor for NODAT in HT patients. The implications of interventions, focusing on preventing or correcting low s-Mg, for the risk of NODAT and for clinical outcomes should be evaluated.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Serum magnesium</kwd><kwd>Diabetes mellitus</kwd><kwd>Heart transplantation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par14">Heart transplantation (HT) is currently the &#x0201c;gold standard&#x0201d; therapy for selected patients with end-stage heart failure. Still, despite significant advances in the field, this treatment is associated with high rates of morbidity and mortality. A major cause of morbidity and mortality following HT is diabetes mellitus: it is known that at 1 and 5&#x000a0;years following HT, 21% and 35% of survivors, respectively, suffer from diabetes [<xref ref-type="bibr" rid="CR1">1</xref>]. In addition to pre-existing diabetes, new-onset diabetes after transplantation (NODAT) may also develop as a complication that has a detrimental impact on patient survival or on other transplant-related adverse events [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par15">Another unfavorable post-HT occurrence may be the development of a magnesium deficiency, to which a possible contributory factor is the administration of calcineurin inhibitors (CNIs), which are known to induce magnesium urinary wasting [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Moreover, MiR-133a-regulated calcineurin-nuclear factor in activated T cells c4 (NFATc4) signalling and DNA methyltransferases-1 (DNMTs-1)-3a is changed in diabetic hearts and has been shown to be associated with a hypertrophic response and cardiac remodeling [<xref ref-type="bibr" rid="CR5">5</xref>]. Indeed, it has been reported that hypomagnesemia frequently develops within the first few weeks following kidney transplantation, with a nadir in the serum magnesium (s-Mg) level in the second month post-transplantation and persistent hypomagnesemia is invariably accompanied by myocardial magnesium depletion in the transplanted heart [<xref ref-type="bibr" rid="CR6">6</xref>]. Several studies have indicated that magnesium deficiency is nonetheless a potentially modifiable risk factor for diabetes in both non-transplant patients and in kidney transplant recipients [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]; it is also known that magnesium in the high-normality range is associated with a lower cardiovascular risk [<xref ref-type="bibr" rid="CR10">10</xref>] and its levels are independently and inversely associated with prediabetes and overt diabetes [<xref ref-type="bibr" rid="CR11">11</xref>]. The molecular basis for the involvement of magnesium in the pathogenesis of diabetes may lie in its role as a co-factor in several pathways, including glucose transport and insulin sensitivity and secretion [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In healthy individuals, binding of insulin to insulin receptor in vitro leads to translocation of magnesium to platelets, leading to reduced platelet aggregation and decreased release of pro-aggregatory agents like thromboxane; this protective effect is lost in diabetics [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par16">Given the high prevalence of both hypomagnesemia and diabetes in HT patients, and the proposed association of low s-Mg with an increased risk for diabetes in non-transplant patients and for NODAT in kidney transplant recipients, we designed a study to determine the association between hypomagnesemia and the incidence of NODAT in HT patients.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and participants</title><p id="Par17">A retrospective cohort study was conducted on all consecutive patients &#x02265;&#x02009;18&#x000a0;years of age who underwent primary HT and follow-up at our medical center from January 2002 to August 2017. The exclusion criteria were the absence of s-Mg measurements, death within the 12&#x000a0;months post-transplant, pre-HT diabetes, or diabetes diagnosed within the first 12&#x000a0;months after HT. Data for each patient were systematically recorded upon intake and during each subsequent visit or medical contact. Donor data were obtained from the National Organ Transplantation Center and from the medical records at the hospitals at which the donors had died. Levels of s-Mg were determined using a colorimetric assay kit (Xylidyl Blue-I Method), and s-creatinine levels, by the kinetic alkaline picrate (Jaffe&#x02019;s) method. Average magnesium levels during the first 12&#x000a0;months following HT were determined for each patient. Low s-Mg was defined as a mean s-Mg level of &#x0003c;&#x02009;1.8 (mg/dL) [<xref ref-type="bibr" rid="CR7">7</xref>]. The institutional protocol for post-transplant immunosuppression therapy was consistent throughout the study period and comprised a CNI, a mycophenolate-based drug, a corticosteroid, and a polyclonal induction agent. From the time that everolimus appeared on the market, it was given to a minority of patients later in the follow-up, combined with a low dose of CNI. Conversion to everolimus was dictated by the patient&#x02019;s risk profile, with the considerations including cytomegalovirus infection, renal failure, allograft vasculopathy and malignancy risk. The study was approved by our institutional review board.</p></sec><sec id="Sec4"><title>Outcomes</title><p id="Par18">Because mean s-Mg of all the s-Mg levels recorded during the first year after HT was the predictor, all outcome measures were assessed from 1&#x000a0;year after HT and beyond. The primary endpoint was NODAT, defined according to the diagnostic criteria of the American Diabetes Association, i.e., hemoglobin A1c level &#x02265;&#x02009;6.5%, fasting plasma glucose &#x02265;&#x02009;126&#x000a0;mg/dL, or random plasma glucose &#x02265;&#x02009;200&#x000a0;mg/dL [<xref ref-type="bibr" rid="CR14">14</xref>]. Secondary outcomes included: (1) all-cause mortality, (2) rejection, and (3) stroke. Stroke was defined according to the updated definition statement of stroke from the American Heart Association/American Stroke Association [<xref ref-type="bibr" rid="CR15">15</xref>]. Rejections were diagnosed by routine or clinically indicated endomyocardial biopsy (EMB) and classified according to the revised ISHLT classification system for rejection [<xref ref-type="bibr" rid="CR16">16</xref>]. Any treated rejection (ATR) that was clinically significant was defined as an event that led to acute augmentation of immunosuppression in conjunction with an ISHLT&#x02009;&#x02265;&#x02009;2R right ventricular EMB result or non-cellular rejection (biopsy-negative rejection) with hemodynamic compromise [<xref ref-type="bibr" rid="CR17">17</xref>]. For each patient, two rejection scores were calculated, as follows. (1) Total rejection score (TRS), as a measure of the severity of the rejection, was calculated according to the following weighting: 0R&#x02009;=&#x02009;0, 1R&#x02009;=&#x02009;1, 2R&#x02009;=&#x02009;2, and 3R&#x02009;=&#x02009;3. (2) Any rejection score (ARS), which reflected the total number of rejections, regardless of their severity, was calculated on the basis of 0R&#x02009;=&#x02009;0, 1R&#x02009;=&#x02009;1, 2R&#x02009;=&#x02009;1, and 3R&#x02009;=&#x02009;1. Each score for each particular patient was normalized by dividing it by the cumulative scores for the total number of biopsy specimens taken during the study period for that patient [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par19">In accordance with the mean value of all s-Mg levels recorded during the first year after HT, patients were divided into high s-Mg (&#x02265;&#x02009;1.8&#x000a0;mg/dL) and low s-Mg (&#x0003c;&#x02009;1.8&#x000a0;mg/dL) groups. Data are presented as mean&#x02009;&#x000b1;&#x02009;standard deviation if normally distributed, or as median and interquartile ranges (IQRs). Continuous variables were tested using the Shapiro&#x02013;Wilk&#x02019;s test for normal distribution. Categorical variables were expressed as frequencies and percentages. The groups were analyzed using the &#x003c7;<sup>2</sup> test for categorical variables and a t-test or Mann&#x02013;Whitney&#x02013;Wilcoxon test, as appropriate, for normal/non-normal distributed continuous variables. Analysis of 15-year NODAT was conducted using the Kaplan&#x02013;Meier curves and compared by the log-rank test.</p><p id="Par20">To explore the independent association of s-Mg and outcomes, a Cox proportional hazards model for 15-year NODAT was constructed. The Cox proportional hazards model for NODAT included the following covariates: recipient s-Mg (dichotomized above or below 1.8&#x000a0;mg/dL), age, gender, body mass index (BMI), immunosuppressive protocol, and the mean of the serum creatinine levels in the 12-months following HT. Covariate selection was based on clinical judgment. Statistical analyses were conducted using R foundation (version 3.5.1) [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Study cohort</title><p id="Par21">Of the original study cohort of 177 consecutive patients for whom first year s-Mg levels were available, 23 patients who died within the first year following HT, 7 patients under the age of 18, and 45 patients who were diagnosed with diabetes mellitus prior to HT or during the first year were excluded from the final analysis. Finally, 102 patients constituted the study population, median age 50 [33, 57]&#x000a0;years, mostly men (70%) with 41% of ischemic etiology.</p><p id="Par22">The study cohort mean and median s-Mg levels were 1.79&#x02009;&#x000b1;&#x02009;0.26&#x000a0;mg/dL and 1.73 [1.61&#x02013;1.91]&#x000a0;mg/dL, respectively. The average dispersion of s-Mg by the time (months) from HT during the first year is given in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. In accordance with the mean value of all s-Mg levels recorded during the first year after HT, patients were divided into high s-Mg (&#x02265;&#x02009;1.8&#x000a0;mg/dL) (n&#x02009;=&#x02009;45) and low s-Mg (&#x0003c;&#x02009;1.8&#x000a0;mg/dL) (n&#x02009;=&#x02009;57) groups. Baseline clinical characteristics of patients in the two groups are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Baseline patient and donor clinical characteristics were similar for the two groups, except higher mean s-Mg levels in the high s-Mg group (2.0&#x02009;&#x000b1;&#x02009;0.3&#x000a0;mg/dL) vs the low s-Mg group (1.6&#x02009;&#x000b1;&#x02009;0.1&#x000a0;mg/dL). CNI therapies (cyclosporine vs tacrolimus) were distributed similarly in the two study groups.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>First year monthly s-Mg (mg/dL) average distribution for the total study cohort</p></caption><graphic xlink:href="12933_2019_939_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics for the two groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">High s-Mg Group<break/>N&#x02009;=&#x02009;45</th><th align="left">Low s-Mg Group<break/>N&#x02009;=&#x02009;57</th><th align="left">p-value</th></tr></thead><tbody><tr><td align="left">Recipient age (years) (median [IQR])</td><td align="left">50 [37&#x02013;57]</td><td align="left">50 [31&#x02013;57]</td><td char="." align="char">0.551</td></tr><tr><td align="left">Donor age (years) (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">31&#x02009;&#x000b1;&#x02009;18</td><td align="left">27&#x02009;&#x000b1;&#x02009;17</td><td char="." align="char">0.332</td></tr><tr><td align="left">Recipient gender (male) (%)</td><td align="left">32 (71)</td><td align="left">39 (68)</td><td char="." align="char">0.939</td></tr><tr><td align="left">Donor gender (female) (%)</td><td align="left">40 (100)</td><td align="left">49 (100)</td><td char="." align="char">1.000</td></tr><tr><td align="left">Etiology (ischemic) (%)</td><td align="left">17 (38)</td><td align="left">25 (44)</td><td char="." align="char">0.677</td></tr><tr><td align="left">Recipient BMI (kg/m<sup>2</sup>) (median [IQR])</td><td align="left">23.7 [21.6&#x02013;26.8]</td><td align="left">23.9 [20.8&#x02013;27]</td><td char="." align="char">0.708</td></tr><tr><td align="left">Donor BMI (kg/m<sup>2</sup>) (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">24.6&#x02009;&#x000b1;&#x02009;3.7</td><td align="left">24.7&#x02009;&#x000b1;&#x02009;2.7</td><td char="." align="char">0.886</td></tr><tr><td align="left">Hypertension (%)</td><td align="left">7 (16)</td><td align="left">16 (28)</td><td char="." align="char">0.207</td></tr><tr><td align="left">Dyslipidemia (%)</td><td align="left">11 (24)</td><td align="left">18 (32)</td><td char="." align="char">0.567</td></tr><tr><td align="left">Past smoker (%)</td><td align="left">9 (20)</td><td align="left">15 (26)</td><td char="." align="char">0.609</td></tr><tr><td align="left">Assist device (%)</td><td align="left">8 (18)</td><td align="left">7 (13)</td><td char="." align="char">0.646</td></tr><tr><td align="left">Status 1 (%)</td><td align="left">30 (67)</td><td align="left">38 (67)</td><td char="." align="char">1.000</td></tr><tr><td align="left">PRA&#x02009;&#x0003e;&#x02009;30% (%)</td><td align="left">0 (0)</td><td align="left">1 (2)</td><td char="." align="char">1.000</td></tr><tr><td align="left" colspan="3">Recipient blood type (%)</td><td char="." align="char">0.371</td></tr><tr><td align="left">&#x000a0;A</td><td align="left">17 (42)</td><td align="left">19 (36)</td><td align="left"/></tr><tr><td align="left">&#x000a0;AB</td><td align="left">4 (10)</td><td align="left">3 (6)</td><td align="left"/></tr><tr><td align="left">&#x000a0;B</td><td align="left">5 (13)</td><td align="left">14 (27)</td><td align="left"/></tr><tr><td align="left">&#x000a0;O</td><td align="left">14 (35)</td><td align="left">16 (31)</td><td align="left"/></tr><tr><td align="left">Recipient creatinine (median [IQR])</td><td align="left">1.11 [1&#x02013;1.3]</td><td align="left">1 [0.9&#x02013;1.2]</td><td char="." align="char">0.232</td></tr><tr><td align="left">Recipient bilirubin (median [IQR])</td><td align="left">1 [0.7&#x02013;1.2]</td><td align="left">1 [0.63&#x02013;1.35]</td><td char="." align="char">0.865</td></tr><tr><td align="left">Tacrolimus<sup>a</sup> (%)</td><td align="left">19 (42)</td><td align="left">30 (53)</td><td char="." align="char">0.398</td></tr><tr><td align="left">Average tacrolimus<sup>a</sup> (median [IQR])</td><td align="left">13 [11.4&#x02013;13.8]</td><td align="left">12.5 [10.4&#x02013;13.7]</td><td char="." align="char">0.400</td></tr><tr><td align="left">Cyclosporine<sup>a</sup> (%)</td><td align="left">14 (31)</td><td align="left">18 (32)</td><td char="." align="char">1.000</td></tr><tr><td align="left">Average cyclosporine<sup>a</sup> (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">296&#x02009;&#x000b1;&#x02009;56</td><td align="left">277&#x02009;&#x000b1;&#x02009;37</td><td char="." align="char">0.276</td></tr><tr><td align="left">Ischemic time (min) (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">169&#x02009;&#x000b1;&#x02009;46</td><td align="left">153&#x02009;&#x000b1;&#x02009;40</td><td char="." align="char">0.102</td></tr><tr><td align="left">PAM (mmHg) (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">35&#x02009;&#x000b1;&#x02009;12</td><td align="left">33&#x02009;&#x000b1;&#x02009;13</td><td char="." align="char">0.550</td></tr><tr><td align="left">CO (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">3.7&#x02009;&#x000b1;&#x02009;1.2</td><td align="left">3.5&#x02009;&#x000b1;&#x02009;1.2</td><td char="." align="char">0.362</td></tr><tr><td align="left">PVR (median [IQR])</td><td align="left">2.2 [1.3&#x02013;3]</td><td align="left">2.3 [1.7&#x02013;3.2]</td><td char="." align="char">0.468</td></tr><tr><td align="left">CMV mismatch (%)</td><td align="left">14 (39)</td><td align="left">11 (33)</td><td char="." align="char">0.819</td></tr><tr><td align="left">Statins post-HT (%)</td><td align="left">41 (91)</td><td align="left">53 (93)</td><td char="." align="char">1.000</td></tr><tr><td align="left">Hypertension post-HT (%)</td><td align="left">29 (64)</td><td align="left">33 (58)</td><td char="." align="char">0.639</td></tr><tr><td align="left">Average Mg in first year (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left">2&#x02009;&#x000b1;&#x02009;0.3</td><td align="left">1.6&#x02009;&#x000b1;&#x02009;0.1</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Average Mg in first month (median [IQR])</td><td align="left">2 [1.9&#x02013;2.2]</td><td align="left">1.7 [1.6&#x02013;1.8]</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Mg&#x02009;&#x0003c;&#x02009;1.8&#x000a0;mg/dL in the first month (%)</td><td align="left">3 (7)</td><td align="left">38 (83)</td><td char="." align="char">&#x0003c;&#x02009;0.001</td></tr></tbody></table><table-wrap-foot><p><italic>SD</italic> standard deviation, <italic>BMI</italic> body mass index, <italic>PRA</italic> panel reactive antibody, <italic>PAM</italic> mean pulmonary pressure, <italic>CO</italic> cardiac output, <italic>PVR</italic> pulmonary vascular resistance, <italic>CMV</italic> cytomegalovirus, <italic>HT</italic> heart transplantation</p><p><sup>a</sup>During first 3&#x000a0;months from HT</p></table-wrap-foot></table-wrap>
</p><p id="Par23">Changes in s-Mg during the first year by low and high s-Mg groups are presented in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. A s-Mg nadir was observed in the second month following HT in the low s-Mg group compared with the fourth month in the high s-Mg group, with similar courses in the two groups. Changes in monthly s-Mg during the first year by immunosuppression therapy (cyclosporine vs tacrolimus) are presented in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. Mean s-Mg levels were lower in the tacrolimus-treated patients than in patients treated with cyclosporine, with a later s-Mg nadir (fourth month vs second month).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>First-year monthly distribution of s-Mg (mg/dL) levels by low and high s-Mg groups</p></caption><graphic xlink:href="12933_2019_939_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>First-year monthly distribution of s-Mg (mg/dL) levels by immunosuppression therapies (patients for whom immunosuppression therapies were crossed were excluded)</p></caption><graphic xlink:href="12933_2019_939_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec8"><title>Association of s-Mg level with NODAT</title><p id="Par24">Kaplan&#x02013;Meier survival analysis demonstrated that 15-year freedom from NODAT was significantly higher in the high s-Mg patients than in the low s-Mg patients (85% vs 46% log-rank test, p&#x02009;&#x0003c;&#x02009;0.001, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Consistently, multivariate analysis adjusted for recipient age, gender, immunosuppression therapies, mean serum creatinine values throughout the first year post-HT, and BMI, revealed that low s-Mg was independently associated with a significant &#x0003e;&#x02009;8-fold increased risk for NODAT (95% CI 2.15&#x02013;32.6, p&#x02009;=&#x02009;0.003, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Kaplan&#x02013;Meier curves for NODAT</p></caption><graphic xlink:href="12933_2019_939_Fig4_HTML" id="MO4"/></fig>
<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Multivariate analysis for NODAT</p></caption><graphic xlink:href="12933_2019_939_Fig5_HTML" id="MO5"/></fig>
</p></sec><sec id="Sec9"><title>Association of s-Mg level with other adverse clinical outcomes</title><p id="Par25">Kaplan&#x02013;Meier analyses showed significantly higher mortality rates in the low s-Mg group (log-rank <italic>p</italic>-value&#x02009;=&#x02009;0.04, Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). This remained consistent after adjustment for recipient age and gender (HR 2.6, 95% CI 1.02&#x02013;6.77, p&#x02009;=&#x02009;0.05). There were no differences in rejection scores between the low and high s-Mg groups (TRS (median [IQR]): 0.27 [0.12, 0.43] vs 0.33 [0.14, 0.47], <italic>p&#x02009;</italic>=&#x02009;0.713; ARS (median [IQR]): 0.25 [0.12, 0.38] vs 0.29 [0.14, 0.41], <italic>p&#x02009;</italic>=&#x02009;0.611, respectively), or in freedom from ATR (log-rank <italic>p</italic>-value&#x02009;=&#x02009;0.289). Stroke rate was significantly higher in patients with low s-Mg levels than in those with high s-Mg (14% vs 0, p&#x02009;=&#x02009;0.025). All strokes were ischemic, with a mean time from HT to event of 5.9&#x02009;&#x000b1;&#x02009;4.0&#x000a0;years. Patients who developed stroke presented with a higher incidence of ischemic vs non-ischemic end-stage heart failure (100% vs 36%, p&#x02009;=&#x02009;0.002), hypertension prior to HT (63% vs 19%, p&#x02009;=&#x02009;0.018) or a history of smoking prior to HT (62% vs 20%, p&#x02009;=&#x02009;0.023). Among these patients, more developed NODAT (75% vs 22%, p&#x02009;=&#x02009;0.005), and the mortality rate was higher vs non-stroke patients (62.5% vs 18.1%, p&#x02009;=&#x02009;0.013, at 15&#x000a0;years).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Kaplan&#x02013;Meier curves for mortality</p></caption><graphic xlink:href="12933_2019_939_Fig6_HTML" id="MO6"/></fig>
</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par26">Diabetes is a major confounder of mortality and morbidity following HT, and therefore every effort should be made to reduce the diabetes burden in HT recipients. To the best of our knowledge, our current study is the first to demonstrate that low s-Mg after HT is independently associated with a significant &#x0003e;&#x02009;8-fold increased risk for NODAT. Additional important findings were that the incidence of stroke was significantly higher in patients with low s-Mg levels compared to those with high s-Mg (14% vs 0, p&#x02009;=&#x02009;0.031) as well as higher mortality rate.</p><p id="Par27">Diabetes is common in HT recipients and is associated with high incidence of infection, cardiac allograft vasculopathy (CAV), graft loss, and reduced survival [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Although risk factors for NODAT in transplant patients are similar to those in the general population (including older age, higher BMI, and male gender), immunosuppressive medications significantly further contribute to NODAT [<xref ref-type="bibr" rid="CR22">22</xref>]. It has been shown that tacrolimus reduces insulin secretion more potently than cyclosporine both in vitro and in vivo [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In the DIRECT trial, the incidence of NODAT was significantly lower for patients treated with cyclosporine than for those receiving tacrolimus [<xref ref-type="bibr" rid="CR24">24</xref>]. In our study cohort, tacrolimus and cyclosporine therapies were equally distributed among the two groups, with similar mean trough levels for the two groups. This distribution, taken together with the Cox proportional hazards model, suggest that hypomagnesemia is an independent risk factor for NODAT.</p><p id="Par28">Diabetes per se may also induce urinary magnesium loss, caused by hyperglycemia, hyperfiltration or a direct effect of insulin on the kidneys&#x02019; magnesium Mg channels [<xref ref-type="bibr" rid="CR25">25</xref>]. In contrast, in the non-diabetes or pre-diabetes general population, serum glucose levels are below the threshold for urinary Mg wasting and are hence unlikely to influence s-Mg levels [<xref ref-type="bibr" rid="CR8">8</xref>]. One of the strengths of our study is thus that by excluding patients with diabetes before the HT or those developing diabetes within the first year after HT, and following s-Mg levels with repeated measurements for 12&#x000a0;months post-HT, while evaluating outcomes beyond 12&#x000a0;months, we precluded reverse causation (as diabetes per se may induce urinary magnesium loss [<xref ref-type="bibr" rid="CR25">25</xref>]).</p><p id="Par29">Hypomagnesemia after transplantation has been attributed to a number of factors: the use of CNIs, which induce urinary loss of magnesium. In this context, a sub-population of L-type Ca2+ channels (LTCCs) has also been identified in caveolae domains that appears critical in regulating &#x003b2;-adrenoceptor and hypertrophic calcineurin/nuclear factor of activated T-cells (NFAT) heading to a reduced ischemic tolerance and lesser cardioprotection [<xref ref-type="bibr" rid="CR26">26</xref>]. Additional factors are loop diuretic agents, which are frequently administered in these patients [<xref ref-type="bibr" rid="CR27">27</xref>], and impaired gastrointestinal absorption of magnesium due to the diarrhea commonly occurring post-HT. It has been shown in kidney transplant patients and non-transplanted patients that lower s-Mg levels are an independent risk factor for new onset diabetes [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. We note that most of these studies showing an association between low s-Mg and diabetes mellitus, were based on a single measurement [<xref ref-type="bibr" rid="CR8">8</xref>], a median or 30-day moving average assessment [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], or s-Mg concentrations measured 1&#x000a0;year apart [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. A retrospective study of kidney transplant recipients evaluating time-dependent exposure (i.e., using 3 monthly time-varying and rolling-average s-Mg levels) indicated that low s-Mg are an independent risk factor for NODAT [<xref ref-type="bibr" rid="CR7">7</xref>]. Another strength of our study is thus that it is based on a comprehensive assessment and repeated consistent measures of s-Mg, along with other detailed clinical parameters, allowing a detailed analysis of the study question. Our analysis thus suggests that it is the consistency of low s-Mg over time that influences the diabetes risk.</p><p id="Par30">The pathophysiological mechanisms underlying the association between hypomagnesemia and NODAT are complex and have not yet been fully elucidated. It has been suggested that a number of mechanisms may provide the molecular and functional basis for the involvement of magnesium in the pathogenesis of diabetes mellitus, as follows: (1) Magnesium is a co-factor necessary for glucose metabolism in several pathways, including transport between membranes, glucose oxidation, and insulin-mediated tyrosine kinase pathways [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], and it may therefore be involved in insulin secretion or insulin signaling [<xref ref-type="bibr" rid="CR34">34</xref>]. Magnesium deficiency has been shown to promote insulin resistance [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], and magnesium supplementation has been reported to improve both glucose tolerance and insulin sensitivity [<xref ref-type="bibr" rid="CR36">36</xref>] in animal and clinical studies in non-transplant patients with diabetes mellitus [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. In addition, it should be pinpointed that after administration of SGLT2 inhibitors, a raise in serum magnesium concentrations (not coupled with a reduced urinary excretion) is associated with a significant improvement in endothelial function, arterial stiffness and renal resistive index [<xref ref-type="bibr" rid="CR39">39</xref>]. (2) Common genetic variations in the magnesium-regulating genes <italic>TRPM6</italic>, <italic>SLC41A2</italic>, <italic>CLDN19</italic>, <italic>CNNM2</italic>, and <italic>FXYD2</italic> have been shown to significantly modify the risk of diabetes through s-Mg levels [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. (3) It is also possible that mitochondrial dysfunction could underlie the association between low s-Mg and NODAT, as both hypomagnesemia and diabetes can result from mitochondrial dysfunction, as found in large pedigree with hypomagnesemia and metabolic syndrome [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. This association is further enforced by the findings in kidney transplant recipients that tacrolimus can cause secondary mitochondrial respiratory chain dysfunction [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par31">Before concluding the Discussion, we touch on two findings that are relevant not only to HT patients but also to the general population at large&#x02014;stroke and calcium metabolism. Prospective studies in large populations have indicated a dose-dependent inverse association between dietary magnesium and stroke incidence [<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>], with a recent meta-analysis reporting a 22% lower risk of stroke in people in the highest vs the lowest categories of dietary magnesium intake [<xref ref-type="bibr" rid="CR47">47</xref>]. Consistent with these findings, we report here a significantly higher rate of cerebrovascular events in patients with low s-Mg. Magnesium depletion has also been associated with multiple biochemical abnormalities, among them bone and calcium metabolism. There is evidence for a suppressive effect of hypomagnesemia on parathyroid hormone secretion and resistance [<xref ref-type="bibr" rid="CR48">48</xref>], further supporting the importance and potential clinical implications of managing low-Mg state in HT patients known to suffer frequently from osteoporosis, partially due to prolonged steroid treatment.</p><p id="Par32">Our findings may have potentially important implications for the management of patients following HT. As hypomagnesemia is a potentially modifiable risk factor for diabetes and NODAT, a number of studies were conducted aiming to verify its clinical implications. In non-transplant populations higher consumption of magnesium was associated with a lower risk of diabetes [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], and in a randomized trial of kidney transplant patients, magnesium supplementation 3&#x000a0;months post-transplant, was shown to improve fasting blood glucose levels [<xref ref-type="bibr" rid="CR51">51</xref>]. The increased s-Mg level observed following SGLT2 inhibition, combined with a favourable cardiovascular profile of these drugs, are suggestive of a therapeutic potential for diabetic and pre-diabetic HT recipients, that should be further studied.</p><p id="Par33">There are several limitations to our study. First, there is the limitation inherent in observational trials that uncovers associations but precludes the determination of cause-and-effect relationships. Second, this study was limited by being based on a single-center experience. Third, measuring s-Mg and not intracellular magnesium levels may influence the assessment of the patients&#x02019; magnesium status. Finally, magnesium intake was not controlled or assessed. Nevertheless, the intake of magnesium should be reflected in the measured s-Mg. Thus, any conclusions drawn from the data must be replicated with a larger sample size and a prospective study design.</p></sec><sec id="Sec11"><title>Conclusion</title><p id="Par34">In conclusion, our study demonstrates that low post-HT s-Mg level is independently associated with an increased risk for NODAT in HT patients. Nevertheless, the implications of interventions, focusing on preventing or correcting low s-Mg, on the risk for NODAT and on clinical outcomes should be further evaluated.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ARS</term><def><p id="Par5">any rejection score</p></def></def-item><def-item><term>BMI</term><def><p id="Par6">body mass index</p></def></def-item><def-item><term>CAV</term><def><p id="Par7">cardiac allograft vasculopathy</p></def></def-item><def-item><term>DM</term><def><p id="Par8">diabetes mellitus</p></def></def-item><def-item><term>EMB</term><def><p id="Par9">endomyocardial biopsy</p></def></def-item><def-item><term>HT</term><def><p id="Par10">heart transplantation</p></def></def-item><def-item><term>ISHLT</term><def><p id="Par11">International Society of Heart and Lung Transplantation</p></def></def-item><def-item><term>NODAT</term><def><p id="Par12">new-onset diabetes after transplantation</p></def></def-item><def-item><term>TRS</term><def><p id="Par13">total rejection score</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>YP: data collection and interpretation, wrote the research project and the full manuscript. ER: wrote the research project and the full manuscript. JL: data collection and interpretation. AT: study revision and editing. EZF: study revision and editing. DV: study revision. RK: statistical analysis and study revision. LS: data collection and interpretation. MS: study revision and editing. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Data collected from a departmental database.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par35">Institutional Ethical Committee (Protocol No 4257).</p></notes><notes><title>Consent for publication</title><p id="Par36">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par37">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khush</surname><given-names>KK</given-names></name><name><surname>Cherikh</surname><given-names>WS</given-names></name><name><surname>Chambers</surname><given-names>DC</given-names></name><name><surname>Goldfarb</surname><given-names>S</given-names></name><name><surname>Hayes</surname><given-names>D</given-names><suffix>Jr</suffix></name><name><surname>Kucheryavaya</surname><given-names>AY</given-names></name><name><surname>Levvey</surname><given-names>BJ</given-names></name><name><surname>Meiser</surname><given-names>B</given-names></name><name><surname>Rossano</surname><given-names>JW</given-names></name><name><surname>Stehlik</surname><given-names>J</given-names></name><etal/></person-group><article-title>The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult heart transplantation report-2018; focus theme: multiorgan transplantation</article-title><source>J Heart Lung Transpl</source><year>2018</year><volume>37</volume><issue>10</issue><fpage>1155</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2018.07.022</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Jung</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Yun</surname><given-names>TJ</given-names></name><name><surname>Kim</surname><given-names>JB</given-names></name><name><surname>Choo</surname><given-names>SJ</given-names></name><name><surname>Chung</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name></person-group><article-title>New-onset diabetes mellitus after heart transplantation- incidence, risk factors and impact on clinical outcome</article-title><source>Circ J</source><year>2017</year><volume>81</volume><issue>6</issue><fpage>806</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-16-0963</pub-id><pub-id pub-id-type="pmid">28344200</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledeganck</surname><given-names>KJ</given-names></name><name><surname>De Winter</surname><given-names>BY</given-names></name><name><surname>Van den Driessche</surname><given-names>A</given-names></name><name><surname>Jurgens</surname><given-names>A</given-names></name><name><surname>Bosmans</surname><given-names>JL</given-names></name><name><surname>Couttenye</surname><given-names>MM</given-names></name><name><surname>Verpooten</surname><given-names>GA</given-names></name></person-group><article-title>Magnesium loss in cyclosporine-treated patients is related to renal epidermal growth factor downregulation</article-title><source>Nephrol Dial Transpl</source><year>2014</year><volume>29</volume><issue>5</issue><fpage>1097</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1093/ndt/gft498</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nijenhuis</surname><given-names>T</given-names></name><name><surname>Hoenderop</surname><given-names>JG</given-names></name><name><surname>Bindels</surname><given-names>RJ</given-names></name></person-group><article-title>Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><issue>3</issue><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000113318.56023.B6</pub-id><pub-id pub-id-type="pmid">14978156</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>N</given-names></name><name><surname>Katare</surname><given-names>R</given-names></name></person-group><article-title>Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides</article-title><source>Cardiovasc Diabetol</source><year>2018</year><volume>17</volume><issue>1</issue><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s12933-018-0684-1</pub-id><pub-id pub-id-type="pmid">29566757</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millane</surname><given-names>TA</given-names></name><name><surname>Jennison</surname><given-names>SH</given-names></name><name><surname>Mann</surname><given-names>JM</given-names></name><name><surname>Holt</surname><given-names>DW</given-names></name><name><surname>McKenna</surname><given-names>WJ</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name></person-group><article-title>Myocardial magnesium depletion associated with prolonged hypomagnesemia: a longitudinal study in heart transplant recipients</article-title><source>J Am Coll Cardiol</source><year>1992</year><volume>20</volume><issue>4</issue><fpage>806</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/0735-1097(92)90177-O</pub-id><pub-id pub-id-type="pmid">1527292</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>JW</given-names></name><name><surname>Famure</surname><given-names>O</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name></person-group><article-title>Hypomagnesemia and the risk of new-onset diabetes mellitus after kidney transplantation</article-title><source>J Am Soc Nephrol</source><year>2016</year><volume>27</volume><issue>6</issue><fpage>1793</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1681/ASN.2015040391</pub-id><pub-id pub-id-type="pmid">26449610</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kieboom</surname><given-names>BCT</given-names></name><name><surname>Ligthart</surname><given-names>S</given-names></name><name><surname>Dehghan</surname><given-names>A</given-names></name><name><surname>Kurstjens</surname><given-names>S</given-names></name><name><surname>de Baaij</surname><given-names>JHF</given-names></name><name><surname>Franco</surname><given-names>OH</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Zietse</surname><given-names>R</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name><name><surname>Hoorn</surname><given-names>EJ</given-names></name></person-group><article-title>Serum magnesium and the risk of prediabetes: a population-based cohort study</article-title><source>Diabetologia</source><year>2017</year><volume>60</volume><issue>5</issue><fpage>843</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1007/s00125-017-4224-4</pub-id><pub-id pub-id-type="pmid">28224192</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Laecke</surname><given-names>S</given-names></name><name><surname>Van Biesen</surname><given-names>W</given-names></name><name><surname>Verbeke</surname><given-names>F</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><name><surname>Peeters</surname><given-names>P</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name></person-group><article-title>Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation</article-title><source>Am J Transpl</source><year>2009</year><volume>9</volume><issue>9</issue><fpage>2140</fpage><lpage>2149</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2009.02752.x</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Gobbo</surname><given-names>LC</given-names></name><name><surname>Imamura</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>JH</given-names></name><name><surname>de Oliveira Otto</surname><given-names>MC</given-names></name><name><surname>Chiuve</surname><given-names>SE</given-names></name><name><surname>Mozaffarian</surname><given-names>D</given-names></name></person-group><article-title>Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies</article-title><source>Am J Clin Nutr</source><year>2013</year><volume>98</volume><issue>1</issue><fpage>160</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.3945/ajcn.112.053132</pub-id><pub-id pub-id-type="pmid">23719551</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Bao</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association of plasma magnesium with prediabetes and type 2 diabetes mellitus in adults</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>12763</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-13050-7</pub-id><pub-id pub-id-type="pmid">28986547</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbagallo</surname><given-names>M</given-names></name><name><surname>Dominguez</surname><given-names>LJ</given-names></name><name><surname>Galioto</surname><given-names>A</given-names></name><name><surname>Ferlisi</surname><given-names>A</given-names></name><name><surname>Cani</surname><given-names>C</given-names></name><name><surname>Malfa</surname><given-names>L</given-names></name><name><surname>Pineo</surname><given-names>A</given-names></name><name><surname>Busardo</surname><given-names>A</given-names></name><name><surname>Paolisso</surname><given-names>G</given-names></name></person-group><article-title>Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X</article-title><source>Mol Aspects Med</source><year>2003</year><volume>24</volume><issue>1&#x02013;3</issue><fpage>39</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/S0098-2997(02)00090-0</pub-id><pub-id pub-id-type="pmid">12537988</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>R</given-names></name><name><surname>Kaur</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name></person-group><article-title>Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies</article-title><source>Cardiovasc Diabetol</source><year>2018</year><volume>17</volume><issue>1</issue><fpage>121</fpage><pub-id pub-id-type="doi">10.1186/s12933-018-0763-3</pub-id><pub-id pub-id-type="pmid">30170601</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamberlain</surname><given-names>JJ</given-names></name><name><surname>Rhinehart</surname><given-names>AS</given-names></name><name><surname>Shaefer</surname><given-names>CF</given-names><suffix>Jr</suffix></name><name><surname>Neuman</surname><given-names>A</given-names></name></person-group><article-title>Diagnosis and management of diabetes: synopsis of the 2016 american diabetes association standards of medical care in diabetes</article-title><source>Ann Intern Med</source><year>2016</year><volume>164</volume><issue>8</issue><fpage>542</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.7326/M15-3016</pub-id><pub-id pub-id-type="pmid">26928912</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>RL</given-names></name><name><surname>Kasner</surname><given-names>SE</given-names></name><name><surname>Broderick</surname><given-names>JP</given-names></name><name><surname>Caplan</surname><given-names>LR</given-names></name><name><surname>Connors</surname><given-names>JJ</given-names></name><name><surname>Culebras</surname><given-names>A</given-names></name><name><surname>Elkind</surname><given-names>MS</given-names></name><name><surname>George</surname><given-names>MG</given-names></name><name><surname>Hamdan</surname><given-names>AD</given-names></name><name><surname>Higashida</surname><given-names>RT</given-names></name><etal/></person-group><article-title>An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association</article-title><source>Stroke</source><year>2013</year><volume>44</volume><issue>7</issue><fpage>2064</fpage><lpage>2089</lpage><pub-id pub-id-type="doi">10.1161/STR.0b013e318296aeca</pub-id><pub-id pub-id-type="pmid">23652265</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>S</given-names></name><name><surname>Winters</surname><given-names>GL</given-names></name><name><surname>Fishbein</surname><given-names>MC</given-names></name><name><surname>Tazelaar</surname><given-names>HD</given-names></name><name><surname>Kobashigawa</surname><given-names>J</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><name><surname>Andersen</surname><given-names>CB</given-names></name><name><surname>Angelini</surname><given-names>A</given-names></name><name><surname>Berry</surname><given-names>GJ</given-names></name><name><surname>Burke</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection</article-title><source>J Heart Lung Transpl</source><year>2005</year><volume>24</volume><issue>11</issue><fpage>1710</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2005.03.019</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>DH</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Nishi</surname><given-names>T</given-names></name><name><surname>Luikart</surname><given-names>H</given-names></name><name><surname>Dimbil</surname><given-names>S</given-names></name><name><surname>Kobashigawa</surname><given-names>J</given-names></name><name><surname>Khush</surname><given-names>K</given-names></name><name><surname>Fearon</surname><given-names>WF</given-names></name></person-group><article-title>Change in lymphocyte to neutrophil ratio predicts acute rejection after heart transplantation</article-title><source>Int J Cardiol</source><year>2018</year><volume>251</volume><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2017.10.060</pub-id><pub-id pub-id-type="pmid">29074043</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raichlin</surname><given-names>E</given-names></name><name><surname>Edwards</surname><given-names>BS</given-names></name><name><surname>Kremers</surname><given-names>WK</given-names></name><name><surname>Clavell</surname><given-names>AL</given-names></name><name><surname>Rodeheffer</surname><given-names>RJ</given-names></name><name><surname>Frantz</surname><given-names>RP</given-names></name><name><surname>Pereira</surname><given-names>NL</given-names></name><name><surname>Daly</surname><given-names>RC</given-names></name><name><surname>McGregor</surname><given-names>CG</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation</article-title><source>J Heart Lung Transpl</source><year>2009</year><volume>28</volume><issue>4</issue><fpage>320</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2009.01.006</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Team RDC</collab></person-group><source>R: a language and environment for statistical computing</source><year>2015</year><publisher-loc>Vienna</publisher-loc><publisher-name>Team RDC</publisher-name></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costanzo</surname><given-names>MR</given-names></name><name><surname>Dipchand</surname><given-names>A</given-names></name><name><surname>Starling</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>M</given-names></name><name><surname>Desai</surname><given-names>S</given-names></name><name><surname>Fedson</surname><given-names>S</given-names></name><name><surname>Fisher</surname><given-names>P</given-names></name><name><surname>Gonzales-Stawinski</surname><given-names>G</given-names></name><name><surname>Martinelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients</article-title><source>J Heart Lung Transpl</source><year>2010</year><volume>29</volume><issue>8</issue><fpage>914</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2010.05.034</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montori</surname><given-names>VM</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Erwin</surname><given-names>PJ</given-names></name><name><surname>Velosa</surname><given-names>JA</given-names></name><name><surname>Gabriel</surname><given-names>SE</given-names></name><name><surname>Kudva</surname><given-names>YC</given-names></name></person-group><article-title>Posttransplantation diabetes: a systematic review of the literature</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><issue>3</issue><fpage>583</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.3.583</pub-id><pub-id pub-id-type="pmid">11874952</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markell</surname><given-names>M</given-names></name></person-group><article-title>New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>43</volume><issue>6</issue><fpage>953</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2004.03.020</pub-id><pub-id pub-id-type="pmid">15168375</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozbay</surname><given-names>LA</given-names></name><name><surname>Smidt</surname><given-names>K</given-names></name><name><surname>Mortensen</surname><given-names>DM</given-names></name><name><surname>Carstens</surname><given-names>J</given-names></name><name><surname>Jorgensen</surname><given-names>KA</given-names></name><name><surname>Rungby</surname><given-names>J</given-names></name></person-group><article-title>Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells</article-title><source>Br J Pharmacol</source><year>2011</year><volume>162</volume><issue>1</issue><fpage>136</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01018.x</pub-id><pub-id pub-id-type="pmid">20825407</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincenti</surname><given-names>F</given-names></name><name><surname>Friman</surname><given-names>S</given-names></name><name><surname>Scheuermann</surname><given-names>E</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Jenssen</surname><given-names>T</given-names></name><name><surname>Campistol</surname><given-names>JM</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Pescovitz</surname><given-names>MD</given-names></name><name><surname>Marchetti</surname><given-names>P</given-names></name><name><surname>Tuncer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus</article-title><source>Am J Transpl</source><year>2007</year><volume>7</volume><issue>6</issue><fpage>1506</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2007.01749.x</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosiello</surname><given-names>L</given-names></name></person-group><article-title>Hypomagnesemia and diabetes mellitus. A review of clinical implications</article-title><source>Arch Intern Med</source><year>1996</year><volume>156</volume><issue>11</issue><fpage>1143</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1001/archinte.1996.00440100029005</pub-id><pub-id pub-id-type="pmid">8639008</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>J</given-names></name><name><surname>Du Toit</surname><given-names>EF</given-names></name><name><surname>Peart</surname><given-names>JN</given-names></name><name><surname>Patel</surname><given-names>HH</given-names></name><name><surname>Headrick</surname><given-names>JP</given-names></name></person-group><article-title>Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection</article-title><source>Cardiovasc Diabetol</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>155</fpage><pub-id pub-id-type="doi">10.1186/s12933-017-0638-z</pub-id><pub-id pub-id-type="pmid">29202762</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Laecke</surname><given-names>S</given-names></name><name><surname>Van Biesen</surname><given-names>W</given-names></name></person-group><article-title>Hypomagnesaemia in kidney transplantation</article-title><source>Transpl Rev (Orlando)</source><year>2015</year><volume>29</volume><issue>3</issue><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.trre.2015.05.002</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheungpasitporn</surname><given-names>W</given-names></name><name><surname>Thongprayoon</surname><given-names>C</given-names></name><name><surname>Harindhanavudhi</surname><given-names>T</given-names></name><name><surname>Edmonds</surname><given-names>PJ</given-names></name><name><surname>Erickson</surname><given-names>SB</given-names></name></person-group><article-title>Hypomagnesemia linked to new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis</article-title><source>Endocr Res</source><year>2016</year><volume>41</volume><issue>2</issue><fpage>142</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.3109/07435800.2015.1094088</pub-id><pub-id pub-id-type="pmid">26934195</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>W</given-names></name><name><surname>Boyle</surname><given-names>S</given-names></name><name><surname>Carroll</surname><given-names>A</given-names></name><name><surname>Bockenhauer</surname><given-names>D</given-names></name><name><surname>Marks</surname><given-names>SD</given-names></name></person-group><article-title>Hypomagnesemia and increased risk of new-onset diabetes mellitus after transplantation in pediatric renal transplant recipients</article-title><source>Pediatr Nephrol</source><year>2017</year><volume>32</volume><issue>5</issue><fpage>879</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1007/s00467-016-3571-6</pub-id><pub-id pub-id-type="pmid">28039534</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinangil</surname><given-names>A</given-names></name><name><surname>Celik</surname><given-names>V</given-names></name><name><surname>Barlas</surname><given-names>S</given-names></name><name><surname>Sakaci</surname><given-names>T</given-names></name><name><surname>Koc</surname><given-names>Y</given-names></name><name><surname>Basturk</surname><given-names>T</given-names></name><name><surname>Akin</surname><given-names>EB</given-names></name><name><surname>Ecder</surname><given-names>T</given-names></name></person-group><article-title>New-onset diabetes after kidney transplantation and pretransplant hypomagnesemia</article-title><source>Prog Transpl</source><year>2016</year><volume>26</volume><issue>1</issue><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1177/1526924816633949</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimura</surname><given-names>E</given-names></name><name><surname>Okuno</surname><given-names>S</given-names></name><name><surname>Yamakawa</surname><given-names>T</given-names></name><name><surname>Inaba</surname><given-names>M</given-names></name><name><surname>Nishizawa</surname><given-names>Y</given-names></name></person-group><article-title>Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients</article-title><source>Magn Res</source><year>2007</year><volume>20</volume><issue>4</issue><fpage>237</fpage><lpage>244</lpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadler</surname><given-names>JL</given-names></name><name><surname>Buchanan</surname><given-names>T</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Antonipillai</surname><given-names>I</given-names></name><name><surname>Bergman</surname><given-names>R</given-names></name><name><surname>Rude</surname><given-names>R</given-names></name></person-group><article-title>Magnesium deficiency produces insulin resistance and increased thromboxane synthesis</article-title><source>Hypertension</source><year>1993</year><volume>21</volume><issue>6 Pt 2</issue><fpage>1024</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.21.6.1024</pub-id><pub-id pub-id-type="pmid">8505087</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yajnik</surname><given-names>CS</given-names></name><name><surname>Smith</surname><given-names>RF</given-names></name><name><surname>Hockaday</surname><given-names>TD</given-names></name><name><surname>Ward</surname><given-names>NI</given-names></name></person-group><article-title>Fasting plasma magnesium concentrations and glucose disposal in diabetes</article-title><source>Br Med J (Clin Res ed)</source><year>1984</year><volume>288</volume><issue>6423</issue><fpage>1032</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1136/bmj.288.6423.1032</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mooren</surname><given-names>FC</given-names></name><name><surname>Kruger</surname><given-names>K</given-names></name><name><surname>Volker</surname><given-names>K</given-names></name><name><surname>Golf</surname><given-names>SW</given-names></name><name><surname>Wadepuhl</surname><given-names>M</given-names></name><name><surname>Kraus</surname><given-names>A</given-names></name></person-group><article-title>Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects&#x02014;a double-blind, placebo-controlled, randomized trial</article-title><source>Diabetes Obes Metab</source><year>2011</year><volume>13</volume><issue>3</issue><fpage>281</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2010.01332.x</pub-id><pub-id pub-id-type="pmid">21205110</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alzaid</surname><given-names>AA</given-names></name><name><surname>Dinneen</surname><given-names>SF</given-names></name><name><surname>Moyer</surname><given-names>TP</given-names></name><name><surname>Rizza</surname><given-names>RA</given-names></name></person-group><article-title>Effects of insulin on plasma magnesium in noninsulin-dependent diabetes mellitus: evidence for insulin resistance</article-title><source>J Clin Endocrinol Metab</source><year>1995</year><volume>80</volume><issue>4</issue><fpage>1376</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">7714113</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Moran</surname><given-names>M</given-names></name><name><surname>Guerrero-Romero</surname><given-names>F</given-names></name></person-group><article-title>Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><issue>4</issue><fpage>1147</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.4.1147</pub-id><pub-id pub-id-type="pmid">12663588</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Ridaura</surname><given-names>R</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name></person-group><article-title>Magnesium intake and risk of type 2 diabetes in men and women</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><issue>1</issue><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.1.134</pub-id><pub-id pub-id-type="pmid">14693979</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villegas</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>Dai</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name></person-group><article-title>Dietary calcium and magnesium intakes and the risk of type 2 diabetes: the Shanghai Women&#x02019;s Health Study</article-title><source>Am J Clin Nutr</source><year>2009</year><volume>89</volume><issue>4</issue><fpage>1059</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2008.27182</pub-id><pub-id pub-id-type="pmid">19225116</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solini</surname><given-names>A</given-names></name><name><surname>Giannini</surname><given-names>L</given-names></name><name><surname>Seghieri</surname><given-names>M</given-names></name><name><surname>Vitolo</surname><given-names>E</given-names></name><name><surname>Taddei</surname><given-names>S</given-names></name><name><surname>Ghiadoni</surname><given-names>L</given-names></name><name><surname>Bruno</surname><given-names>RM</given-names></name></person-group><article-title>Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study</article-title><source>Cardiovasc Diabetol</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>138</fpage><pub-id pub-id-type="doi">10.1186/s12933-017-0621-8</pub-id><pub-id pub-id-type="pmid">29061124</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Chacko</surname><given-names>SA</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Eaton</surname><given-names>CB</given-names></name><name><surname>Wu</surname><given-names>WC</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>Genetic variations in magnesium-related ion channels may affect diabetes risk among African American and Hispanic American women</article-title><source>J Nutr</source><year>2015</year><volume>145</volume><issue>3</issue><fpage>418</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3945/jn.114.203489</pub-id><pub-id pub-id-type="pmid">25733456</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Hsu</surname><given-names>YH</given-names></name><name><surname>Niu</surname><given-names>T</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>Common genetic variants of the ion channel transient receptor potential membrane melastatin 6 and 7 (TRPM6 and TRPM7), magnesium intake, and risk of type 2 diabetes in women</article-title><source>BMC Med Genet</source><year>2009</year><volume>10</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/1471-2350-10-4</pub-id><pub-id pub-id-type="pmid">19149903</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>FH</given-names></name><name><surname>Hariri</surname><given-names>A</given-names></name><name><surname>Farhi</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>KF</given-names></name><name><surname>Toka</surname><given-names>HR</given-names></name><name><surname>Nelson-Williams</surname><given-names>C</given-names></name><name><surname>Raja</surname><given-names>KM</given-names></name><name><surname>Kashgarian</surname><given-names>M</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><etal/></person-group><article-title>A cluster of metabolic defects caused by mutation in a mitochondrial tRNA</article-title><source>Science</source><year>2004</year><volume>306</volume><issue>5699</issue><fpage>1190</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1126/science.1102521</pub-id><pub-id pub-id-type="pmid">15498972</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavira</surname><given-names>B</given-names></name><name><surname>Gomez</surname><given-names>J</given-names></name><name><surname>Diaz-Corte</surname><given-names>C</given-names></name><name><surname>Llobet</surname><given-names>L</given-names></name><name><surname>Ruiz-Pesini</surname><given-names>E</given-names></name><name><surname>Ortega</surname><given-names>F</given-names></name><name><surname>Coto</surname><given-names>E</given-names></name></person-group><article-title>Mitochondrial DNA haplogroups and risk of new-onset diabetes among tacrolimus-treated renal transplanted patients</article-title><source>Gene</source><year>2014</year><volume>538</volume><issue>1</issue><fpage>195</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2014.01.036</pub-id><pub-id pub-id-type="pmid">24445060</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adebamowo</surname><given-names>SN</given-names></name><name><surname>Spiegelman</surname><given-names>D</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Rexrode</surname><given-names>KM</given-names></name></person-group><article-title>Association between intakes of magnesium, potassium, and calcium and risk of stroke: 2 cohorts of US women and updated meta-analyses</article-title><source>Am J Clin Nutr</source><year>2015</year><volume>101</volume><issue>6</issue><fpage>1269</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.3945/ajcn.114.100354</pub-id><pub-id pub-id-type="pmid">25948665</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>SC</given-names></name><name><surname>Orsini</surname><given-names>N</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name></person-group><article-title>Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies</article-title><source>Am J Clin Nutr</source><year>2012</year><volume>95</volume><issue>2</issue><fpage>362</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.3945/ajcn.111.022376</pub-id><pub-id pub-id-type="pmid">22205313</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>ZL</given-names></name><name><surname>Wang</surname><given-names>ZM</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>ZP</given-names></name><name><surname>Wang</surname><given-names>SK</given-names></name></person-group><article-title>Magnesium intake and incidence of stroke: meta-analysis of cohort studies</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2013</year><volume>23</volume><issue>3</issue><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2012.04.015</pub-id><pub-id pub-id-type="pmid">22789806</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Imam</surname><given-names>MU</given-names></name><name><surname>Ping</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies</article-title><source>BMC Med</source><year>2016</year><volume>14</volume><issue>1</issue><fpage>210</fpage><pub-id pub-id-type="doi">10.1186/s12916-016-0742-z</pub-id><pub-id pub-id-type="pmid">27927203</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agus</surname><given-names>ZS</given-names></name></person-group><article-title>Hypomagnesemia</article-title><source>J Am Soc Nephrol</source><year>1999</year><volume>10</volume><issue>7</issue><fpage>1616</fpage><lpage>1622</lpage><pub-id pub-id-type="pmid">10405219</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopping</surname><given-names>BN</given-names></name><name><surname>Erber</surname><given-names>E</given-names></name><name><surname>Grandinetti</surname><given-names>A</given-names></name><name><surname>Verheus</surname><given-names>M</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Maskarinec</surname><given-names>G</given-names></name></person-group><article-title>Dietary fiber, magnesium, and glycemic load alter risk of type 2 diabetes in a multiethnic cohort in Hawaii</article-title><source>J Nutr</source><year>2010</year><volume>140</volume><issue>1</issue><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.3945/jn.109.112441</pub-id><pub-id pub-id-type="pmid">19889808</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>ZM</given-names></name><name><surname>Hu</surname><given-names>XS</given-names></name><name><surname>Yuan</surname><given-names>BJ</given-names></name><name><surname>Gibson</surname><given-names>R</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Garg</surname><given-names>M</given-names></name></person-group><article-title>Association between magnesium: iron intake ratio and diabetes in Chinese adults in Jiangsu Province</article-title><source>Diabet Med</source><year>2008</year><volume>25</volume><issue>10</issue><fpage>1164</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1111/j.1464-5491.2008.02558.x</pub-id><pub-id pub-id-type="pmid">19046194</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Laecke</surname><given-names>S</given-names></name><name><surname>Nagler</surname><given-names>EV</given-names></name><name><surname>Taes</surname><given-names>Y</given-names></name><name><surname>Van Biesen</surname><given-names>W</given-names></name><name><surname>Peeters</surname><given-names>P</given-names></name><name><surname>Vanholder</surname><given-names>R</given-names></name></person-group><article-title>The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial</article-title><source>Transpl Int</source><year>2014</year><volume>27</volume><issue>9</issue><fpage>895</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1111/tri.12287</pub-id><pub-id pub-id-type="pmid">24909487</pub-id></element-citation></ref></ref-list></back></article>